Previous Close | 2.7400 |
Open | 2.8500 |
Bid | 2.6500 x 100 |
Ask | 2.8000 x 100 |
Day's Range | 2.5100 - 2.9000 |
52 Week Range | 2.5000 - 46.0000 |
Volume | |
Avg. Volume | 81,907 |
Market Cap | 5.177M |
Beta (5Y Monthly) | -0.57 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -24.4000 |
Earnings Date | Mar 31, 2024 - Apr 05, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 165.00 |
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the closing on March 21, 2024 of its previously announced registered direct offering priced at-the-market under the Nasdaq rules for the sale and issuance of 1,542,112 shares of common stock (or prefunded warrants in lieu thereof) of the Company and warrants to purchase up to 1,542,112 shares of commo
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it has entered into definitive agreements for the sale and issuance of 1,542,112 shares of common stock (or prefunded warrants in lieu thereof) of the Company and warrants to purchase up to 1,542,112 shares of common stock at a combined offering price of $4.215 per share of common stock (or per p
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the Korean Patent Office has issued a Notice of Patent Grant for a broad patent that covers the use of Genprex's lead drug candidate, Reqorsa® Immunogene Therapy, in combination with anti-PD-1 and PD-L1 antibodies through 2037.